Primary HPV-based Cervical Cancer Screening Algorithms in Botswana

Cervical Cancer Clinical Trial

Official title: Performance of Two-stage Cervical Cancer Screening Algorithms Using Primary High-risk Human Papillomavirus Testing in Botswana

Status Active, not recruiting

Clinical Trial Summary

Primary high-risk human papillomavirus (HPV) testing has become first line screening for cervical cancer in high-income countries. The feasibility of this approach in low- and middle-income countries (LMICs) is less clear, as is the role of HPV testing among women living with human immunodeficiency virus (HIV). The proposed study seeks to evaluate the accuracy of cervical cancer screening algorithms using primary HPV testing followed by various forms of visual evaluation, including visual inspection with acetic acid (VIA), colposcopy and automated visual evaluation (AVE) for the detection of high-grade cervical dysplasia, using histology as the gold standard. We will validate the AmpFire Assay for HPV self-sampling in our setting. We will determine safe screening intervals in women living with HIV (WLHIV) in an HPV-based cervical cancer screening program and compare triage strategies for positive HPV results at WHO recommended screening intervals for WLHIV. We also seek to understand in-depth the attitudes, acceptability and preferences regarding cervical cancer screening, HPV testing, and self-sampling, for women in Botswana through interviews of a sub-set of women recruited for the cervical cancer screening study. Finally, we will analyze the cost of two-stage cervical cancer screening algorithms using high-risk HPV testing in Botswana.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cervical Cancer
• Prevention
• Uterine Cervical Neoplasms

• NCT number: NCT04242823
• Study type: Interventional
• Source: Beth Israel Deaconess Medical Center
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 22, 2021
• Completion date: February 1, 2027